Sanjeev A. Datar

Sanjeev A. Datar

Auto-generated profile, based on publicly available information

Sanjeev A. Datar

University of California

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Open access
MSMichael Smith
Michael Smith
SCSam Chiacchia
Sam Chiacchia
JBJason Boehme
Jason Boehme
SDSanjeev A. Datar
Sanjeev A. Datar
EMEmily Morell
Emily Morell
JFJeffrey R. Fineman
Jeffrey R. Fineman
We present novel insight into the circulating microRNA profiles of pediatric patients with pulmonary hypertension. Our findings support the utility of microRNAs as both useful biomarkers of disease severity and potential therapeutic targets in pediatric pulmonary hypertension.

1 October 2025 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
MSMichael Smith
Michael Smith
EGEleana S. Guardado
Eleana S. Guardado
JBJason Boehme
Jason Boehme
SDSanjeev A. Datar
Sanjeev A. Datar
EMEmin Maltepe
Emin Maltepe
JFJeffrey R. Fineman
Jeffrey R. Fineman
In this study, we utilize an ovine model of congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) to unveil the structural and transcriptional changes that underlie the maintenance of an adaptively hypertrophied right ventricle (RV). In CHD-PAH, the RV hypertrophies while maintaining microvascular density and expanding its cardiomyocyte population, structural and cellular adaptations that are critical to supporting RV function. These findings provide novel insight into myocardial growth mechanisms that are triggered by congenital pressure overload.

14 December 2023 in Critical Care Medicine
Verified
Journal Article
Open access
YAYoussef Ahmed
Youssef Ahmed
SBStephen Bennett
Stephen Bennett
JBJason Boehme
Jason Boehme
DTDavid Teitel
David Teitel
JFJeffrey Fineman
Jeffrey Fineman
SDSanjeev Datar
Sanjeev Datar

7 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SDSanjeev A. Datar
Sanjeev A. Datar
NWNicholas Werry
Nicholas Werry
ABAustin R. Brown
Austin R. Brown
DFDevon S. Fitzpatrick
Devon S. Fitzpatrick
OFOluwafemi Falade
Oluwafemi Falade
AEAlison L. Van Eenennaam
Alison L. Van Eenennaam
Pulmonary Arterial Hypertension (PAH) is a rare vascular disorder characterized by elevated pressure in pulmonary arteries, eventually leading to right ventricular failure. Approximately 50% of pediatric disease and 20% of adult disease can be linked to a genetic mutation, with nearly 70% of these cases involving mutations in the bone morphogenetic protein receptor type 2 ( BMPR2 ) locus. Investigations using rodent models have made significant advances in our understanding of BMPR2 signaling; however, limited data exist regarding the onset and course of PAH, and etiologies for phenotypic expression in these patients remain unknown. In this work, we describe the development of a novel ovine model of heritable PAH. Because homozygous disruption of BMPR2 is embryonic lethal, we developed heterozygous BMPR2 sheep by using a PAM-disrupting synonymous single stranded oligodeoxyribonucleotide alongside a single guide RNA and Cas9 mediated gene editing strategy. The resulting BMPR2 (+/–) lambs demonstrated cardiac and pulmonary vascular pathology that are consistent with BMPR2 mutation-driven PAH observed in humans. Given the genetic and physiological similarities of BMPR2 (+/–) sheep to humans with heritable PAH, this large animal model will serve as a vital platform for mechanistic molecular studies and will provide a much-needed pre-clinical model for extensive treatment evaluations.